文献速递肺结节与肺癌间质性肺疾病

晚期非小细胞肺癌合并间质性肺疾病患者免疫检查点抑制剂治疗的临床结局:系统评价与Meta分析

Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
PubMed 文献 · Chest · 2022-01-11

该系统评价与Meta分析检索了截至2021年4月的PubMed、EMBASE和Cochrane Library,纳入10项研究共179例患者,评估合并间质性肺疾病(ILD)的非小细胞肺癌(NSCLC)患者接受免疫检查点抑制剂(ICI)治疗的安全性和有效性。结果显示,合并ILD患者的客观缓解率(ORR)显著高于无ILD患者(OR 1.99, 95%CI 1.31-3.00),但任何级别和3级及以上检查点抑制剂肺炎(CIP)的发生率也显著增高(OR 3.23, 95%CI 2.06-5.06;OR 2.91, 95%CI 1.47-5.74)。

要点

  • 合并ILD的NSCLC患者接受ICI治疗的ORR为34%,显著高于无ILD患者。
  • 合并ILD患者任何级别CIP发生率为27%,3级及以上为15%,均显著高于无ILD患者。
  • 尽管CIP发生率较高,但多为轻度且易于管理,临床使用ICI时需谨慎。

核心结论

  • 程序性细胞死亡蛋白1/程序性细胞死亡配体1抑制剂在合并ILD的NSCLC患者中具有较好的疗效。
  • 合并ILD患者接受ICI治疗时CIP常见但多轻微且易于管理,临床医生应谨慎使用ICI。

研究设计与样本

  • 系统检索PubMed、EMBASE和Cochrane Library截至2021年4月,无语言或研究设计限制。
  • 纳入10项研究共179例患者,收集安全性和有效性数据。
  • 主要终点为免疫治疗临床疗效和免疫相关不良事件发生率,尤其是检查点抑制剂肺炎(CIP)。

主要发现

  • 合并ILD患者的汇总ORR为34%(95%CI 20-47),DCR为66%(95%CI 56-75)。
  • 合并ILD患者ORR显著高于无ILD患者(OR 1.99, 95%CI 1.31-3.00)。
  • 合并ILD患者DCR不劣于无ILD患者(汇总OR 1.46, 95%CI 0.94-2.25)。
  • 合并ILD患者任何级别CIP发生率为27%(95%CI 17-37),3级及以上为15%(95%CI 9-22);无ILD患者分别为10%(95%CI 6-13)和4%(95%CI 2-6)。
  • 合并ILD患者任何级别和3级及以上CIP发生率均显著高于无ILD患者(OR 3.23, 95%CI 2.06-5.06;OR 2.91, 95%CI 1.47-5.74)。

关键数值与推荐

  • 合并ILD患者ORR为34%(95%CI 20-47),DCR为66%(95%CI 56-75)。
  • 合并ILD患者任何级别CIP发生率27%(95%CI 17-37),3级及以上15%(95%CI 9-22)。
  • 无ILD患者任何级别CIP发生率10%(95%CI 6-13),3级及以上4%(95%CI 2-6)。

临床怎么用

  • 对于合并ILD的晚期NSCLC患者,ICI治疗可能带来生存获益,但需警惕CIP风险。
  • 临床决策时应权衡疗效与CIP风险,加强CIP监测和管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with non-small cell lung cancer (NSCLC) and preexisting interstitial lung disease (ILD) are often excluded from clinical trials of immune checkpoint inhibitors (ICIs), leaving a gap in knowledge. RESEARCH QUESTION: What are the clinical outcomes of ICIs in patients with NSCLC and preexisting ILD? STUDY DESIGN AND METHODS: Systematic searches were conducted of PubMed, EMBASE, and Cochrane Library through April 2021 with no language or study design restrictions. Studies reporting the safety and efficacy data among patients with cancer and ILD receiving ICI therapy were collected. The primary end points were clinical efficacy to immunotherapy and the incidence of immune-related adverse events, especially for checkpoint inhibitor pneumonitis (CIP). RESULTS: A total of 179 patients in 10 studies were included. The pooled overall response rate (ORR) and pooled disease control rate (DCR) were 34% (95% CI, 20-47) and 66% (95% CI, 56-75), respectively. The ORR in patients with preexisting ILD was significantly higher than that in patients without ILD (OR, 1.99; 95% CI, 1.31-3.00). The DCR and progression-free survival in patients with preexisting ILD were not inferior to those without ILD (pooled OR, 1.46; 95% CI, 0.94-2.25 for DCR). The pooled incidences of any grade and grade 3 or higher CIP were 27% (95% CI, 17-37) and 15% (95% CI, 9-22) in patients with preexisting ILD, and 10% (95% CI, 6-13) and 4% (95% CI, 2-6) in patients without ILD. Meta-analysis found a significantly higher incidence rate of any grade and grade 3 or higher CIP in patients with NSCLC and preexisting ILD than in those patients without ILD (OR, 3.23 [95% CI, 2.06-5.06]; OR, 2.91 [95% CI, 1.47-5.74]). INTERPRETATION: Programmed cell death protein 1/programmed cell death ligand 1 inhibitors had favorable efficacy in NSCLC with preexisting ILD. CIP is frequent in patients with preexisting ILD who receive ICI therapy but is often mild and easily manageable. Clinicians should be cautious when using ICIs in patients with preexisting ILD.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Zhang M, Fan Y, Nie L, et al. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis. Chest. 2022. PMID: 35026298. doi:10.1016/j.chest.2021.12.656

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。